GRFS vs TAK vs AMGN vs IQV vs CRL

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Grifols, S. A. (GRFS) offers the better valuation at 12. 0x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate Grifols, S. A. (GRFS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 12. 0x versus Takeda Pharmaceutical Company Limited at 77. 4x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Amgen Inc. 's 5. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +46. 2%, compared to -52. 8% for Grifols, S. A. (GRFS). Over 10 years, the gap is even starker: IQV returned +166. 5% versus GRFS's -35. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 367% more volatile than TAK relative to the S&P 500. On balance sheet safety, Takeda Pharmaceutical Company Limited (TAK) carries a lower debt/equity ratio of 65% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 7. 5% for TAK. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Amgen Inc. 's 5. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 16. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.

In this comparison, TAK (3.

6% yield), AMGN (2. 9% yield), GRFS (2. 6% yield) pay a dividend. IQV, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), 3. 6% yield). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TAK: -1. 4%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRFS is a small-cap deep-value stock; TAK is a mid-cap income-oriented stock; AMGN is a mid-cap quality compounder stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock. GRFS, TAK, AMGN pay a dividend while IQV, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.